Zacks.com on MSN7d
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial CancerGSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...
Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore the potential of cancer prevention through vaccination. The partnership, ...
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...
GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...
The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for ...
GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...
La Comisión Europea ha aprobado el fármaco 'JEMPERLI' (dostarlimab), de GSK, en combinación con la quimioterapia estándar ...
European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback